Comment on “Accelerated biological aging and postoperative acute kidney injury in surgical patients: a retrospective multicentre cohort analysis of 94 006 cases” Authors: YiQing Yang, Jing Hu Published: 2026 Dear Editor, We read with interest the multicenter retrospective cohort study by Yin et al on accelerated biological aging, quantified by PhenoAge acceleration and postoperative acute kidney injury (AKI) in 94 006 surgical patients[1]. The authors should be commended for introducing a scalable, biomarker-based aging measure into perioperative risk assessment and to examine not only overall AKI but also severe AKI and length of stay in a large, heterogeneous surgical population. This study showed that PhenoAge acceleration provides predictive information beyond chronological age and standard clinical risk factors for postoperative AKI and stages 2–3 AKI[1]. The fact that biological age can be estimated from routine preoperative laboratory tests makes this approach realistically implementable in many hospitals. Similar associations have been reported in recent studies, where clinical biomarker-based age acceleration was more strongly related to chronic kidney disease progression, cardiovascular events, and mortality than calendar age alone, suggesting that “biological age” reflects broader, multi-organ vulnerability relevant to perioperative care[2,3]. Epigenetic clocks and other molecular aging indices have also been linked to frailty, disability, and postoperative complications, further supporting the potential role of aging biomarkers in surgical risk assessment[4]. Simultaneously, several caveats should be considered before PhenoAge acceleration is incorporated into routine clinical decision-making. First, the metric was derived from a single set of routine tests obtained within 30 days prior to surgery[1]. Such cross-sectional data do not capture long-term aging trajectories or short-term reversibility, and the temporal stability of PhenoAge acceleration in surgical patients is not yet clear. Second, missing data on inflammatory markers such as C-reactive protein and the use of imputation introduce measurement uncertainty that may influence effect estimates despite the authors’ sensitivity analyses[1]. Third, as with any retrospective analysis, there is a risk of residual confounding from unmeasured factors, including detailed preoperative medication exposure, nutritional status, frailty, and intraoperative fluid and vasopressor management, all of which may affect the AKI risk and have been highlighted in other perioperative AKI studies[5]. Finally, the cohort comes from academic centers in a single country, so external validation in other health systems and more diverse populations is needed to determine generalizability. In our view, it would be helpful if future research considered at least three questions. First, can the added predictive value of PhenoAge acceleration be reproduced in prospective, multi-ethnic surgical cohorts when compared directly with established clinical scores? Second, how stable is this metric over time, and how does it perform relative to physical frailty instruments and molecular clocks, such as epigenetic aging indices, in explaining variations in perioperative outcomes?[3,4] Third, can biological age be used not only for risk stratification but also as a target or stratifier in intervention studies – for example, prehabilitation programmes or tailored hemodynamic and nephroprotective strategies for patients with high biological age – and does such targeting translate into lower AKI incidence and fewer perioperative complications? In summary, Yin et al provided large-scale evidence that accelerated biological aging identifies surgical patients at increased risk of postoperative AKI, severe AKI, and greater resource use[1]. With external validation and prospective, intervention-focused studies, phenoage acceleration and related biological age measures may become useful complements to chronological age and existing risk scores, supporting more refined perioperative decision-making and more targeted preventive strategies.